Home > Insider Trading > Filing (0001193805-21-000974)

Filing Details

Accession Number:: 0001193805-21-000974
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-07-02 17:07:18
Reporting Period:: 2021-06-30

Accepted Time:: 2021-07-02 17:07:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1374690	Larimar Therapeutics Inc.	LRMR	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1009258	Deerfield Management Company, L.p. (Series C)	345 Park Avenue South, 12Th Floor New York NY 10010	Yes	No	Yes	Yes
1352546	E James Flynn	345 Park Avenue South, 12Th Floor New York NY 10010	Yes	No	Yes	Yes
1603333	Deerfield Private Design Fund Iii, L.p.	345 Park Avenue South, 12Th Floor New York NY 10010	Yes	No	Yes	Yes
1610540	Deerfield Mgmt Iii, L.p.	345 Park Avenue South, 12Th Floor New York NY 10010	Yes	No	Yes	Yes
1646981	Deerfield Healthcare Innovations Fund, L.p.	345 Park Avenue South, 12Th Floor 37Th Floor New York NY 10010	Yes	No	Yes	Yes
1665736	Deerfield Mgmt Hif, L.p.	345 Park Avenue South, 12Th Floor 37Th Floor New York NY 10010	Yes	No	Yes	Yes
1680307	Deerfield Private Design Fund Iv, L.p.	345 Park Avenue South, 12Th Floor New York NY 10010	Yes	No	Yes	Yes
1713467	Deerfield Mgmt Iv, L.p.	345 Park Avenue South, 12Th Floor New York NY 10010	Yes	No	Yes	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-06-30	228,569	$8.75	1,943,406	No	4	P	Indirect	Through Deerfield Private Design Fund III, L.P.
Common Stock	Acquisiton	2021-06-30	228,571	$8.75	1,943,423	No	4	P	Indirect	Through Deerfield Private Design Fund IV, L.P.
Common Stock	Acquisiton	2021-06-30	228,570	$8.75	1,943,420	No	4	P	Indirect	Through Deerfield Healthcare Innovations Fund, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	Through Deerfield Private Design Fund III, L.P.
No	4	P	Indirect	Through Deerfield Private Design Fund IV, L.P.
No	4	P	Indirect	Through Deerfield Healthcare Innovations Fund, L.P.

Footnotes

The shares reported herein as being held through Deerfield Private Design Fund III, L.P. ("Fund III"), Deerfield Private Design Fund IV, L.P. ("Fund IV") and Deerfield Healthcare Innovations Fund, L.P. ("Deerfield HIF" and, collectively with Fund III and Fund IV, the "Funds") include shares that were previously reported as being held indirectly through Chondrial Therapeutics Holdings, LLC ("Chondrial"), which shares were distributed to the Funds pursuant to a pro rata distribution to the members of Chondrial.
This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Fund III. Deerfield Mgmt IV, L.P. is the general partner of Fund IV. Deerfield Mgmt HIF, L.P. is the general partner of Deerfield HIF. Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.
In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.